During the corresponding conference call, ICON CEO, defendant Stephen Cutler, revealed that two of ICON’s large pharmaceutical customers had materially curtailed upcoming FSP trial work due to ongoing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results